A new Phase 1 study is investigating the tolerability of the PD1 antibody Nivolumab in the treatment of meningioma neoplastica. For the first time, the drug is being administered intrathecally - i.e. directly into the cerebrospinal fluid and thus at the site of the disease - in Europe. The multicenter study is led by Professor Dr. Dr. Ghazaleh Tabatabai.
Press Release (in German only)
Professor Dr. Dr. Ghazaleh Tabatabai
Copyright: Verena Müller / UKT
